Reuters logo
BRIEF-Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint
September 21, 2017 / 9:05 PM / in 3 months

BRIEF-Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint

Sept 21 (Reuters) - Versartis Inc

* Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint

* Versartis Inc - Study ‍did not meet its primary endpoint of non-inferiority.​

* Versartis Inc says ‍somavaratan was well tolerated with treatment discontinuation rate lower than for genotropin arm.​

* Versartis Inc - ‍No new emergent safety signals were observed in the study​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below